Skip to main content

Patient registration

Please fill out this registration form with your patient to get them access to the support program that best fits their needs. For patients under 18 years of age, please enroll their primary caregiver. Please obtain the appropriate consent from the patient or caregiver as noted on the form.

You can also download the form, fill it out, and fax it back.

information tooltip icon
If under 18, please register the patient's primary caregiver
information tooltip icon
You will have the opportunity to answer questions about the caregiver and patient.
information tooltip icon
First, you will answer questions about a patient who is also a caregiver to someone with a condition affecting their pancreas. Then, you will have the opportunity to add information about a dependent patient.

*Eligibility: Available to patients with commercial prescription insurance coverage for CREON® (pancrelipase) who meet eligibility criteria. Neither co-pay assistance nor multivitamins/nutritional supplements are available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offers subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit or call 1-844-662-7366 for additional information.  For full Terms and Conditions for CREON CF patients, visit or call 1-855-227-3493 for additional information.  To learn about AbbVie’s privacy practices and your privacy choices, visit

Indications and Important Safety


CREON® (pancrelipase) delayed-release capsules are indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.

Important Safety Information

  • Fibrosing colonopathy has been reported following treatment with pancreatic enzyme products. Do not exceed the recommended dosage of 2,500 lipase units/kg/meal (or 10,000 lipase units/kg/day) or 4,000 lipase units/g fat ingested/day in adult and pediatric patients greater than 12 months of age without further investigation.
  • To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
  • Pancreatic enzyme products contain purines that may increase blood uric acid levels. High dosages have been associated with hyperuricosuria and hyperuricemia. Consider monitoring blood uric acid levels in patients with gout, renal impairment, or hyperuricemia during treatment with CREON.
  • There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
  • Severe hypersensitivity reactions including anaphylaxis, asthma, hives, and pruritus have been reported with pancreatic enzyme products. Monitor patients with a known hypersensitivity reaction to proteins of porcine origin for hypersensitivity reactions during treatment with CREON.
  • Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
  • Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.

Reference: 1. CREON [package insert]. North Chicago, IL: AbbVie Inc.

  1. Reference:
  2. CREON [package insert]. North Chicago, IL: AbbVie Inc.